LFG316
Total Payments
$442,919
Transactions
21
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $4,000 | 1 | 0 |
| 2018 | $17,039 | 2 | 0 |
| 2017 | $421,880 | 18 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $442,919 | 21 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED ACTIVE CONTROLLED OPEN LABEL MULTIPLE DOSE PROOF OF CONCEPT STUDY OF INTRAVITREAL LFG316 IN PATIENTS WITH MULTIFOCAL CHOROIDITIS MFC | Novartis Pharmaceuticals Corporation | $228,604 | 0 |
| OPEN LABEL PARALLEL GROUP DRUG DRUG INTERACTION STUDY IN END STAGE RENAL DISEASE PATIENTS AWAITING KIDNEY TRANSPLANT TO INVESTIGATE THE POTENTIAL EFFECT OF IVIG TREATMENT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LFG316 | Novartis Pharmaceuticals Corporation | $123,868 | 0 |
| A RANDOMIZED OPEN LABEL CONTROLLED MULTIPLE DOSE STUDY TO EVALUATE THE CLINICAL EFFICACY SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LFG316 IN PATIENTS WITH TRANSPLANT ASSOCIATED MICROANGIOPATHY AFTER HEMATOPOIETIC PRECURSOR CELL TRANSPLANTATION | Novartis Pharmaceuticals Corporation | $90,447 | 0 |
Top Doctors Receiving Payments for LFG316
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $442,919 | 21 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $442,919
Product Information
- Type Drug
- Total Payments $442,919
- Total Doctors 0
- Transactions 21
About LFG316
LFG316 is a drug associated with $442,919 in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $4,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for LFG316 is "Unspecified" ($442,919, 100.0% of total).
LFG316 is associated with 3 research studies, including "A RANDOMIZED ACTIVE CONTROLLED OPEN LABEL MULTIPLE DOSE PROOF OF CONCEPT STUDY OF INTRAVITREAL LFG316 IN PATIENTS WITH MULTIFOCAL CHOROIDITIS MFC" ($228,604).